DE10119946A1 - Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance - Google Patents
Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performanceInfo
- Publication number
- DE10119946A1 DE10119946A1 DE10119946A DE10119946A DE10119946A1 DE 10119946 A1 DE10119946 A1 DE 10119946A1 DE 10119946 A DE10119946 A DE 10119946A DE 10119946 A DE10119946 A DE 10119946A DE 10119946 A1 DE10119946 A1 DE 10119946A1
- Authority
- DE
- Germany
- Prior art keywords
- increasing
- carnitine
- creatine
- effervescent tablet
- addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 22
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract description 14
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 14
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 14
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 11
- 229960003624 creatine Drugs 0.000 title claims abstract description 11
- 239000006046 creatine Substances 0.000 title claims abstract description 11
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 8
- 235000019197 fats Nutrition 0.000 title description 2
- 238000001243 protein synthesis Methods 0.000 title description 2
- 230000014616 translation Effects 0.000 title description 2
- 102000008934 Muscle Proteins Human genes 0.000 title 1
- 108010074084 Muscle Proteins Proteins 0.000 title 1
- 238000007792 addition Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet is new.
Description
Die Erfindung betrifft eine Zugabe zu einer an sich üblichen Brausetablette. Die Zugabe hat einen Gehalt an mindestens einem der folgenden Bestandteile: CLA (konjungierte Linolsäure), L-Carnitin, Kreatin. The invention relates to an addition to a conventional effervescent tablet. The addition contains at least one of the following components: CLA (conjugated linoleic acid), L-carnitine, creatine.
Die Brausetablette ist dadurch gekennzeichnet, daß sie mindestens einen der folgenden Zusatzstoffe enthält: CLA (konjungierte Linolsäure), L-Carnitin, Kreatin. The effervescent tablet is characterized in that it has at least one of the following Additives contains: CLA (conjugated linoleic acid), L-carnitine, creatine.
Im Gegensatz zu den bisherigen bekannten Darreichungsformen als z. B. Tabletten werden CLA und/oder L-Carnitin und/oder Kreatin als Zusatz zu einer Brausetablette dargereicht. In contrast to the previously known dosage forms as z. B. tablets are CLA and / or L-carnitine and / or creatine as an addition to an effervescent tablet presented.
Die oben genannten Inhaltsstoffe besitzen mindestens eine der folgenden
Eigenschaften:
- - Steigerung der Proteinsynthese im Muskel
- - Steigerung der Fettverbrennung
- - Steigerung der Leistungsfähigkeit
- - Steigerung des Aufbaues fettfreier Muskelmasse
- - Förderung der körpereigenen Energieproduktion
- - Verbesserung der Vitalität
- - Normalisierung des Stoffwechsels
- - Einfluß auf den Energiestoffwechsel der Skelettmuskulatur
- - Einfluß auf schnellere kurzzeitig Regenerierung von ATP-Vorräten
- - Increased protein synthesis in the muscle
- - Increase fat burning
- - Increase in performance
- - Increase in building lean muscle mass
- - Promotion of the body's energy production
- - Improve vitality
- - normalization of metabolism
- - Influence on the energy metabolism of the skeletal muscles
- - Influence on faster short-term regeneration of ATP stocks
Die vorliegende Erfindung hat das Ziel, eine schneller resorbierbare und magenfreundliche Dareichung von CLA und/oder L-Carnitin und/oder Kreatin zu Darreichung von CLA und/oder L-Carnitin und/oder Kreatin in Tablettenform erzielen. Bei der Darreichung verzögert sich die erwünschte Wirkung dadurch, daß die Tablette sich erst im Magen auflösen muß. Als Bestandteil einer Brausetablette kommen CLA und/oder L-Carnitin und/oder Kreatin aber erheblich schneller zur Wirkung und sind erheblich magenfreundlicher, da die Magensäfte die Tablette nicht erst auflösen müssen. Eine zusätzliche Zufuhr von CLA und/oder L-Carnitin und/oder Kreatin ist sinnvoll, um Defizite bei starken körperlichen Anstrengungen auszugleichen und die körperliche Leistungsfähigkeit zu steigern. The present invention aims to provide a more absorbable and stomach-friendly administration of CLA and / or L-carnitine and / or creatine Administration of CLA and / or L-carnitine and / or creatine in tablet form achieve. When administered, the desired effect is delayed in that the The tablet first has to dissolve in the stomach. As part of an effervescent tablet CLA and / or L-carnitine and / or creatine come much faster Effect and are considerably more stomach-friendly since the gastric juices do not affect the tablet have to dissolve first. An additional supply of CLA and / or L-carnitine and / or Creatine is useful to compensate for deficits during heavy physical exertion and increase physical performance.
Die erfindungsgemäßen Zugaben zu einer Brausetablette sind:
CLA
L-Carnitin
Kreatin
The additions to an effervescent tablet according to the invention are:
CLA
L-carnitine
creatine
Es können ein oder mehrere der genannten Bestandteile enthalten sein. Der Schutz soll Gültigkeit haben, wenn mindestens einer der oben genannten Inhaltsstoffe als Zusatz beigegeben wird. One or more of the ingredients mentioned can be included. The protection should be valid if at least one of the above Ingredients are added as an additive.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119946A DE10119946A1 (en) | 2001-04-24 | 2001-04-24 | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119946A DE10119946A1 (en) | 2001-04-24 | 2001-04-24 | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10119946A1 true DE10119946A1 (en) | 2003-04-30 |
Family
ID=7682463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10119946A Withdrawn DE10119946A1 (en) | 2001-04-24 | 2001-04-24 | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE10119946A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007113540A2 (en) * | 2006-04-05 | 2007-10-11 | The University Of Nottingham | Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling garnitine content in muscle |
| DE102007009649A1 (en) * | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Food supplement for cosmetic care and treatment of the skin, contains at least two cosmetically-active substances, especially conjugated linoleic acid, L-carnitine or its derivatives and-or mate tea extract |
| WO2011072320A1 (en) * | 2009-12-14 | 2011-06-23 | Jubilent Global Limited | Effervescent l-carnitine-based composition |
| CN114343170A (en) * | 2021-12-30 | 2022-04-15 | 北京康比特体育科技股份有限公司 | A kind of effervescent tablet containing creatine and preparation method thereof |
| EP4027990A4 (en) * | 2019-10-16 | 2023-10-18 | Capsugel Belgium NV | Method and composition for increasing muscle protein synthesis |
| EP4027991A4 (en) * | 2019-10-16 | 2023-11-22 | Capsugel Belgium NV | Method and composition for increasing muscle protein synthesis |
-
2001
- 2001-04-24 DE DE10119946A patent/DE10119946A1/en not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007113540A2 (en) * | 2006-04-05 | 2007-10-11 | The University Of Nottingham | Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling garnitine content in muscle |
| WO2007113540A3 (en) * | 2006-04-05 | 2008-03-13 | Univ Nottingham | Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling carnitine content in muscle |
| DE102007009649A1 (en) * | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Food supplement for cosmetic care and treatment of the skin, contains at least two cosmetically-active substances, especially conjugated linoleic acid, L-carnitine or its derivatives and-or mate tea extract |
| WO2008104270A2 (en) * | 2007-02-26 | 2008-09-04 | Beiersdorf Ag | Food supplements for looking after and/or improving the appearance of the skin |
| WO2008104270A3 (en) * | 2007-02-26 | 2009-11-26 | Beiersdorf Ag | Food supplements for looking after and/or improving the appearance of the skin |
| WO2011072320A1 (en) * | 2009-12-14 | 2011-06-23 | Jubilent Global Limited | Effervescent l-carnitine-based composition |
| AU2009356961B2 (en) * | 2009-12-14 | 2016-05-19 | Jubilent Global Limited | Effervescent L-carnitine-based composition |
| EP4027990A4 (en) * | 2019-10-16 | 2023-10-18 | Capsugel Belgium NV | Method and composition for increasing muscle protein synthesis |
| EP4027991A4 (en) * | 2019-10-16 | 2023-11-22 | Capsugel Belgium NV | Method and composition for increasing muscle protein synthesis |
| CN114343170A (en) * | 2021-12-30 | 2022-04-15 | 北京康比特体育科技股份有限公司 | A kind of effervescent tablet containing creatine and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0874618B1 (en) | Preparation for improving hair growth, the skin structure and/or nail regeneration | |
| CH642541A5 (en) | ESSENTIAL SOLUTION CONTAINING AMINO ACIDS FOR ADMINISTRATION TO CANCER PATIENTS. | |
| DE3213284A1 (en) | ANTI-CARIES CHEWING GUM | |
| EP1283054A4 (en) | Drugs for complications of diabetes and neuropathy and utilization thereof | |
| EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| CA2140361A1 (en) | Composition and methods for decreasing muscle breakdown | |
| DE10119946A1 (en) | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance | |
| DE2305980A1 (en) | MINERAL SALT PREPARATION | |
| DE1667887C2 (en) | Amino acid solution for parenteral infusion | |
| CH621333A5 (en) | ||
| DE102013104897A1 (en) | Active substance for the treatment of sarcopenia | |
| DE102006036887B4 (en) | Composition for a means of care, growth promotion and strengthening of skin, hair and nails and its use | |
| DE69533742T2 (en) | Use of proline and / or derivatives as anti-hepatitis agents | |
| DE3421644C2 (en) | ||
| WO1996033707A1 (en) | Topical preparation for promoting muscular development | |
| DE3632791A1 (en) | AGENT AGAINST AGE CHANGES | |
| CA2305764A1 (en) | Bile acid salts of metals with physiological action and the use thereof in therapy | |
| DE2523394A1 (en) | PHARMACEUTICAL PREPARATION | |
| EP0340540A2 (en) | Agent for the prophylaxis of a heart infarct and for the prevention of another infarct | |
| DE2117852A1 (en) | Retarded release tablet and process for its manufacture | |
| WO2007031291A2 (en) | Foodstuff additive | |
| DE2753140C2 (en) | Medicines used to treat stomach ulcers | |
| DE68905392T2 (en) | PENICILLINE FOR RECTAL ADMINISTRATION. | |
| DE3225491A1 (en) | PHARMACEUTICAL COMPOSITION, ITS PRODUCTION AND USE | |
| DE2635293A1 (en) | SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |